Krystal Biotech, Inc. (KRYS) Stock Price & Analysis
Krystal Biotech, Inc. (KRYS) rose 2.35% to USD 335.19 as of July 25, 2026 at 03:08 UTC, according to Nexqual real-time market data.
KRYS last closed at USD 327.5; the session ranged USD 326.01–338.58 on volume of 509,588 shares. Market capitalization is $9.88B, with a 52-week range of USD 130.5–382.54 (NMS). Source: Nexqual, July 25, 2026 at 03:08 UTC.
Key Statistics (as of July 25, 2026 at 03:08 UTC)
| Price | USD 335.19 |
|---|---|
| Change | ▲ 2.35% (up) |
| Previous Close | USD 327.5 |
| Open | USD 327.55 |
| Day Range | USD 326.01 – 338.58 |
| 52-Week Range | USD 130.5 – 382.54 |
| Volume | 509,588 shares |
| Market Cap | $9.88B |
| Exchange | NMS |
Technical Analysis (KRYS)
Nexqual's technical model rates KRYS "NEUTRAL" based on 3 bullish and 3 bearish signals across 125 daily candles, as of July 25, 2026 at 03:08 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 47.62 (neutral) |
| vs SMA50 | Above (USD 332.02) |
| MACD | -0.3 (negative) |
Analyst Ratings (KRYS)
Wall Street analysts rate KRYS "Strong Buy" based on 8 analysts, with a mean price target of USD 376.75 (range USD 284–474), per Nexqual as of July 25, 2026 at 03:08 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 376.75 |
| High Target | USD 474 |
| Low Target | USD 284 |
| Buy / Hold / Sell | 10 / 1 / 0 |
Earnings (KRYS)
| Next Earnings Date | 2026-08-03 |
|---|---|
| EPS Estimate | USD 1.91 |
| Revenue Estimate | $122.10M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.83 vs est 1.42 ▲ beat |
| 2025-12-31 | USD 1.7 vs est 1.61 ▲ beat |
| 2025-09-30 | USD 2.66 vs est 1.12 ▲ beat |
| 2025-06-30 | USD 1.29 vs est 1.44 ▼ miss |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
Financials & Fundamentals (KRYS)
| Total Revenue | $417.30M |
|---|---|
| Revenue Growth (YoY) | +31.90% |
| Gross Margin | +94.17% |
| Operating Margin | +46.14% |
| Profit Margin | +53.92% |
| ROE | +19.90% |
| Debt / Equity | 0.71 |
| Current Ratio | 9.46 |
| Total Cash | $823.40M |
| Total Debt | $9.11M |
| Free Cash Flow | $137.49M |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
Financial Health Score (KRYS)
Nexqual rates Krystal Biotech, Inc.'s overall financial health "Strong" across five dimensions, as of July 25, 2026 at 03:08 UTC.
| Growth | Strong — Revenue +34% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 94%, operating 46% |
| Balance Sheet | Strong — $823M cash vs $9M debt, net cash position |
| Cash Flow | Strong — FCF $137M, 35% margin |
| Efficiency | Solid — ROE 20%, ROA 9.0% |
Ownership (KRYS)
| Insider Ownership | +10.97% |
|---|---|
| Institutional Ownership | +99.57% |
| Shares Outstanding | 29.48M |
| Float | 23.42M |
| Short % of Float | +19.59% |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
Leadership (KRYS)
Krystal Biotech, Inc. is led by Krish S. Krishnan M.B.A., M.S. (age 60), Founder, Chairman, President & CEO, per Nexqual as of July 25, 2026 at 03:08 UTC.
| Founder, Chairman, President & CEO | Krish S. Krishnan M.B.A., M.S. (age 60) |
|---|---|
| Founder, President of R & D and Director | Suma M. Krishnan (age 60) |
| Vice President of North American Sales & Marketing | John Karakkal |
| Senior Vice President of Corporate Development | Stephane Paquette |
| Senior Director & Head of US Human Resources | Josh Suskin |
Major Backers & Investors (KRYS)
Notable institutional backers of Krystal Biotech, Inc. include FMR, LLC, Avoro Capital Advisors LLC, Fidelity, according to Nexqual as of July 25, 2026 at 03:08 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.84% |
| Avoro Capital Advisors LLC | 9.8% |
| Fidelity | 8.78% |
| Soleus Capital Management, L.P. | 3.91% |
| Capital Group | 2.8% |
| SmallCap World Fund Inc | 2.55% |
| Redmile Group, LLC | 2.28% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 20.69% |
| Vanguard Group | 14.92% |
| State Street | 5.54% |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
From Krystal Biotech, Inc.'s Latest SEC 10-K Filing (filed 2026-02-17)
Key Strengths & Strategy (as disclosed to the SEC)
- Our Redosable Gene Therapy Platform We believe that certain inherent features of the HSV-1 virus, combined with the modifications we have made to the viral backbone provides our proprietary gene therapy platform with specific advantages over other viral and non-viral vector platforms and represents an opportunity to generate a portfolio of highly differentiated and potentially first-in-class or best-in-class genetic medicines.
- Since our first commercial launch of VYJUVEK in the United States, we have reported $730.3 million in net product revenue. 6 Regulatory Status On May 19, 2023, the FDA approved VYJUVEK, the first ever redosable gene therapy, for treating patients, six months of age or older, suffering from DEB.
- KB408 KB408 is an inhaled (nebulized) formulation of our proprietary vector, designed to deliver two copies of the SERPINA1 transgene that encodes functional, full-length human AAT protein, for the treatment of AATD.
- In support of the Phase 2 study, we developed and validated a décolleté-specific photonumeric scale ("JDWS") which was submitted to the FDA in the second half of 2025.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 102.1 | ▼ 1.8% |
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 83.73 | ▲ 0.01% |
| ARGX | argenx SE | USD 918.22 | ▲ 7.81% |
| PTGX | Protagonist Therapeutics, Inc. | USD 136.11 | ▲ 0.49% |
| MDGL | Madrigal Pharmaceuticals, Inc. | USD 544.51 | ▲ 1.28% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:08 UTC. This page is informational and not investment advice.